Saturday, June 06, 2015 5:24:35 AM
wow, what a big pill, pardon the medical pun if you will, to swallow.
My question in all of this is as and if the digestion period second half of the year culminates , will this be paid for through addition/dilution of the existing float or will the good Dr. pony up those shares that he owns which I know would be a mere pipe dream to his stockholders? With the absorption of Bio that has a profit, what p/e ratio would we be looking at with Opko's losses that are accumulating? This might be a whiff of magic by the good Dr. but its going to take quite sometime for all this to come together and show fruition proof of the pudding.Another Q? does the Bio shareholders have to vote on this takeover and do they have a takeover poison pill in there company pocket?
Did the board of Bio have controlling interest of the company to accept the good Dr.s generous offering?
No wonder Cramer needs to hear from Bio, so do I.
FWIW, I had my suspicions just last week as to why the Dr. had ceased in buying company shares as of late.This was not typical. I knew it wasn't a Rayaldy FDA fast track announcement or FDA approval, this quite time of the Dr. was signifying something was amiss.It was uncharacteristic of the stock to ascend without the Dr.s endorsement in doing so buying and adding shares.This stock will likely be stuck in a trading digestion range for months or until RLDY gets FDA approval. I don't see the Dr. accumulating any shares now for the forseeable future.jmho
Also, I'm hoping this marriage goes down without a hitch because the tentacles that BIO adds to OPKO is endless and this company will grow beyond anyones ken.Here's to our success good Dr.!
My question in all of this is as and if the digestion period second half of the year culminates , will this be paid for through addition/dilution of the existing float or will the good Dr. pony up those shares that he owns which I know would be a mere pipe dream to his stockholders? With the absorption of Bio that has a profit, what p/e ratio would we be looking at with Opko's losses that are accumulating? This might be a whiff of magic by the good Dr. but its going to take quite sometime for all this to come together and show fruition proof of the pudding.Another Q? does the Bio shareholders have to vote on this takeover and do they have a takeover poison pill in there company pocket?
Did the board of Bio have controlling interest of the company to accept the good Dr.s generous offering?
No wonder Cramer needs to hear from Bio, so do I.
FWIW, I had my suspicions just last week as to why the Dr. had ceased in buying company shares as of late.This was not typical. I knew it wasn't a Rayaldy FDA fast track announcement or FDA approval, this quite time of the Dr. was signifying something was amiss.It was uncharacteristic of the stock to ascend without the Dr.s endorsement in doing so buying and adding shares.This stock will likely be stuck in a trading digestion range for months or until RLDY gets FDA approval. I don't see the Dr. accumulating any shares now for the forseeable future.jmho
Also, I'm hoping this marriage goes down without a hitch because the tentacles that BIO adds to OPKO is endless and this company will grow beyond anyones ken.Here's to our success good Dr.!
Recent OPK News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/15/2026 08:38:03 PM
- OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies • GlobeNewswire Inc. • 05/12/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:04:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:01:43 PM
- OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform • GlobeNewswire Inc. • 04/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:06:14 PM
- OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results • GlobeNewswire Inc. • 04/28/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas • GlobeNewswire Inc. • 04/22/2026 12:00:00 PM
- OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:25:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:16:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:50:09 PM
- OPKO Health to Participate in the Jefferies Biotech on the Beach Summit • GlobeNewswire Inc. • 02/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:07:43 PM
- OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/26/2026 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2026 09:11:42 PM
- OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/19/2025 09:05:00 PM
- NextPlat Reports Third Quarter 2025 Results • PR Newswire (US) • 11/13/2025 01:03:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2025 08:12:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2025 08:11:05 PM
